TAMIBAROTENE CAPSULE PREPARATION
    1.
    发明申请
    TAMIBAROTENE CAPSULE PREPARATION 有权
    TAMIBAROTENE胶囊制剂

    公开(公告)号:US20100048708A1

    公开(公告)日:2010-02-25

    申请号:US12593866

    申请日:2008-03-28

    申请人: Hisao Ekimoto

    发明人: Hisao Ekimoto

    IPC分类号: A61K31/196 A61P35/00

    摘要: The present invention provides a practical preparation form of Tamibarotene and dosage form thereof, which exhibit high absorptivity by the body with minimized toxicity, and which are safe and stable without any risk of contamination. It is provided a Tamibarotene capsule preparation which encapsulates a composition comprising an oil component as its base and Tamibarotene as an active ingredient dissolved in the base. It is preferred that the oil component be propylene glycol fatty acid esters or polyethylene glycols. It is also preferred that the Tamibarotene capsule preparation comprise 0.1-50 mg/mL of the Tamibarotene based on the oil component.

    摘要翻译: 本发明提供了Tamibarotene及其剂型的实用制剂形式,它以体积最小的毒性显示出高吸收性,并且是安全和稳定的,没有任何污染的风险。 提供了一种Tamibarotene胶囊制剂,其包含以油组分为基础的组合物和作为活性成分溶解在基质中的Tamibarotene。 油成分优选为丙二醇脂肪酸酯或聚乙二醇。 还优选的是,Tamibarotene胶囊制剂包含基于油组分的0.1-50mg / mL的Tamibarotene。

    Therapeutic Agent for Metastatic Cancer and Cancer Metastasis Inhibitor
    2.
    发明申请
    Therapeutic Agent for Metastatic Cancer and Cancer Metastasis Inhibitor 审中-公开
    转移癌和癌转移抑制剂的治疗剂

    公开(公告)号:US20080069901A1

    公开(公告)日:2008-03-20

    申请号:US11792519

    申请日:2005-12-06

    申请人: Hisao Ekimoto

    发明人: Hisao Ekimoto

    IPC分类号: A61K33/24 A61P35/00

    摘要: To provide a therapeutic agent for metastatic cancer and a cancer metastasis inhibitor which are highly safe and efficaciously treat metastatic cancer and inhibit cancer metastasis, and especially efficaciously treat and inhibit cancer metastasis to bone and liver. There are provided a therapeutic agent for metastatic cancer and a cancer metastasis inhibitor each of which includes a platinum complex having an anticancer activity as an active ingredient. The platinum complex is preferably cisplatin. The therapeutic agent for metastatic cancer is advantageously usable for treating metastatic cancer to bone and/or liver. The cancer metastasis inhibitor is advantageously usable as a cancer metastasis inhibitor for inhibiting metastasis to bone and/or liver. These agents can advantageously further include a bisphosphonate as another active ingredient.

    摘要翻译: 提供高度安全,有效地治疗转移性癌症并抑制癌症转移的转移癌治疗剂和癌症转移抑制剂,特别是有效治疗和抑制对骨和肝癌的转移。 提供了用于转移性癌症的治疗剂和癌症转移抑制剂,其各自包括具有抗癌活性的铂络合物作为活性成分。 铂络合物优选为顺铂。 用于转移性癌症的治疗剂有利地用于治疗对骨和/或肝的转移性癌症。 癌转移抑制剂有利地用作癌转移抑制剂,用于抑制对骨和/或肝的转移。 这些试剂可以有利地进一步包括双膦酸盐作为另一活性成分。

    Platinum complexes
    3.
    发明授权
    Platinum complexes 失效
    铂复合物

    公开(公告)号:US5130450A

    公开(公告)日:1992-07-14

    申请号:US688903

    申请日:1991-04-19

    IPC分类号: C07F15/00

    CPC分类号: C07F15/0093

    摘要: A platinum (II) complex represented by the general formula: ##STR1## [wherein A's are each ammonia or two A's jointly represent 1,2-diaminocyclohexane, 1-amino-1-aminomethylcyclohexane or 1,4-diamino-2-methylbutane; and B's may be same or different and represent ##STR2## (wherein m is 0, 1 or 2; n is 0 or 1; R.sub.1 is a C.sub.3 -C.sub.6 alkyl group substituted with one or two hydroxyl groups) or two B's jointly represent ##STR3## (wherein R.sub.2 is a C.sub.2 -C.sub.5 alkyl group substituted with one hydroxyl group)].These platinum (II) complexes have high potencies for use as an antitumor agent.

    KIT FOR CANCER TREATMENT AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
    6.
    发明申请
    KIT FOR CANCER TREATMENT AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT 审中-公开
    用于癌症治疗的癌症治疗和药物组合物

    公开(公告)号:US20120277295A1

    公开(公告)日:2012-11-01

    申请号:US13547758

    申请日:2012-07-12

    申请人: Hisao EKIMOTO

    发明人: Hisao EKIMOTO

    摘要: To provide a kit for cancer treatment and a pharmaceutical composition for cancer treatment that can inhibit the growth of tumors and cancers in mammals more than ever.The kit for cancer treatment includes a combination of two different drugs in a kit formulation. The first drug contains a synthetic retinoid or a pharmaceutically acceptable organic or inorganic acid addition salt thereof, and the second drug contains a chemotherapeutic agent for cancer treatment. A synthetic retinoid that can be suitably used is a benzoic acid derivative represented by the following formula (I): or a pharmaceutically acceptable organic or inorganic acid addition salt thereof.

    摘要翻译: 提供用于癌症治疗的试剂盒和用于癌症治疗的药物组合物,其可以比以往任何时候都能抑制哺乳动物肿瘤和癌症的生长。 用于癌症治疗的试剂盒包括两种不同药物在试剂盒配方中的组合。 第一种药物含有合成的类视色素或其药学上可接受的有机或无机酸加成盐,第二种药物含有癌症治疗用化学治疗剂。 可合适地使用的合成类视黄醇是由下式(I)表示的苯甲酸衍生物或其药学上可接受的有机酸或无机酸加成盐。

    Tamibarotene capsule preparation
    7.
    发明授权
    Tamibarotene capsule preparation 有权
    他米巴罗汀胶囊制剂

    公开(公告)号:US08252837B2

    公开(公告)日:2012-08-28

    申请号:US12593866

    申请日:2008-03-28

    申请人: Hisao Ekimoto

    发明人: Hisao Ekimoto

    IPC分类号: A61K31/195 A61K9/48

    摘要: The present invention provides a practical preparation form of Tamibarotene and dosage form thereof, which exhibit high absorptivity by the body with minimized toxicity, and which are safe and stable without any risk of contamination. It is provided a Tamibarotene capsule preparation which encapsulates a composition comprising an oil component as its base and Tamibarotene as an active ingredient dissolved in the base. It is preferred that the oil component be propylene glycol fatty acid esters or polyethylene glycols. It is also preferred that the Tamibarotene capsule preparation comprise 0.1-50 mg/mL of the Tamibarotene based on the oil component.

    摘要翻译: 本发明提供了Tamibarotene及其剂型的实用制剂形式,它以体积最小的毒性显示出高吸收性,并且是安全和稳定的,没有任何污染的风险。 提供了一种Tamibarotene胶囊制剂,其包含以油组分为基础的组合物和作为活性成分溶解在基质中的Tamibarotene。 油成分优选为丙二醇脂肪酸酯或聚乙二醇。 还优选的是,Tamibarotene胶囊制剂包含基于油组分的0.1-50mg / mL的Tamibarotene。